Aslı KURUOĞLU, Hale YAPICI ESER, Hatice Ayşe BORA

Depression and Parkinson disease: prevalence, temporal relationship, and determinants

Background/aim: Comorbidity of depression in Parkinson disease (PD) is a major factor that changes patients quality of life. However, the neurobiological and sociodemographic risk factors for this comorbidity are not well studied. In this study, we aimed to define the prevalence, temporal relationship, and psychosocial and clinical determinants of depression comorbid with PD. Materials and methods: Fifty-five PD patients were evaluated with SCID, a data form that assessed sociodemographic and PD-related variables, UPDRS III, HAM-D, HAM-A, MMSE, and the Apathy Evaluation Scale. Results: Depression (lifetime: 45.5%, last month: 25.5%, before PD: 20%) was the most frequent psychiatric diagnosis. The major determinants of depression in the last month and depression before PD were early onset of PD and young age. Patients on pramipexole treatment were less likely to be diagnosed with depression in the last month. Other sociodemographic and PD-related variables were not significantly different for lifetime, last month, and pre-PD depression diagnosis compared to their counterparts. Conclusion: Depression is prevalent both before and after patient gets a PD diagnosis. Depression is not only the result of PD-related life changes but it is also a preceding factor that may decrease the age of PD onset.

PDF

___

1. Ebadi M. Pfeiffer RF. Parkinsons Disease. Boca Raton, FL, USA: CRC Press; 2005.
2. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003; 26: 81-104.
3. Starkstein S, Merello M. Psychiatric and Cognitive Disorders in Parkinsons Disease. Cambridge, UK: Cambridge University Press; 2002.
4. Gómez-Esteban JC, Tijero B, Somme J, Ciordia R, Berganzo K, Rouco I, Bustos JL, Valle MA, Lezcano E, Zarranz JJ. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinsons disease. J Neurol 2011; 258: 494-499.
5. Naismith SL, Hickie IB, Lewis SJ. The role of mild depression in sleep disturbance and quality of life in Parkinsons disease. J Neuropsychiatry Clin Neurosci 2010; 22: 384-389.
6. Sjödahl Hammarlund C, Hagell P, Nilsson MH. Motor and non-motor predictors of illness-related distress in Parkinsons disease. Parkinsonism Relat Disord 2012; 18: 299-302.
7. Bernal-Pacheco O, Limotai N, Go CL, Fernandez HH. Nonmotor manifestations in Parkinson disease. Neurologist 2012; 18: 1-16.
8. van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinsons disease: effects of disease stage, motor subtype and gender. J Neurol Sci 2011; 310: 220-224.
9. Hsu YT, Liao CC, Chang SN, Yang YW, Tsai CH, Chen TL, Sung FC. Increased risk of depression in patients with Parkinsons disease: a nationwide cohort study. Am J Geriatr Psychiatry 2015; 23: 934-940.
10. Dissanayaka NN, OSullivan JD, Silburn PA, Mellick GD. Assessment methods and factors associated with depression in Parkinsons disease. J Neurol Sci 2011; 310: 208-210.
11. Fernandez HH, See RH, Gary MF, Bowers D, Rodriguez RL, Jacobson C, Okun MS. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. J Geriatric Psychiatry Neurol 2009; 22: 223-227.
12. Dewey RB Jr, Taneja A, McClintock SM, Cullum CM, Dewey RB, Bernstein I, Husain MM. Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression. Cogn Behav Neurology 2012; 25: 115-120.
13. Arabia G, Grossardt BR, Geda YE, Carlin JM, Bower JH, Ahlskog JE, Maraganore DM, Rocca DA. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry 2007; 64: 1385-1392.
14. Ellgring H, Seiler S, Nagel U, Perleth B, Gasser T, Oertel WH. Psychosocial problems of Parkinson patients: approaches to assessment and treatment. Adv Neurol 1990; 53:349-353.
15. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinsons disease. Lancet Neurol 2006; 5: 75-86.
16. Sarandöl A, Eker SS, Sivrioğlu SE, Özkaya G, Erer S, Zarifoğlu M, Kırlı S. Parkinson hastalarında psikiyatrik bozuklukların araştırılması. Yeni Symposium 2002; 45: 74-79 (in Turkish).
17. Büchtemann D, Luppa M, Bramesfeld A, Riedel-Heller S. Incidence of late life depression: a systematic review. J Affect Disord 2012; 142: 172-179.
18. Kuloğlu M, Çayköylü A, Akyol ES, İbiloğlu A, Özer ÖA. Bir eğitim hastanesinde konsultasyonla depresyon tanısı alan vakaların özellikleri. Kriz Dergisi 2007; 15: 9 (in Turkish).
19. Nilsson FM, Kessing LV, Sorenson TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinsons disease: a register-based study. Acta Psychiatr Scand 2002; 106: 202-211.
20. Moretti R, Torre P, Antonello RM, Rosin MV, Esposito F, Furman MR, Bellini G. Apathy: a complex symptom specific to the clinical pattern of presentation of Parkinsons disease? Am J Alzheimers Dis Other Dement 2012; 27: 196-201.
21. Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, Mehdom M, Deuschl G, Krack P. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinsons disease. J Neuropsychiatry Clin Neurosci 2006; 18: 397-401.
22. Reichmann H, Odin P, Brecht HM, Koster J, Kraus PH. Changing dopamine agonist treatment in Parkinsons disease: experiences with switching to pramipexole. J Neural Transm 2006; 71: 17-25.
23. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003; 110: 1119-1127.
24. Yasui N, Sekiguchi K, Hamaguchi H, Kanda F. The effect of pramipexole on depressive symptoms in Parkinsons disease. Kobe J Med Sci 2011; 56: E214-219.
25. Ghorpade S, Tripathi R, Sonawane D, Manjrekar N. Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioural models of depression in rats. J Basic Clin Physiol Pharmacol 2011; 22: 109-114.
26. Benes H, Mattern W, Peglau I, Dreykluft T, Bergmann L, Hansen C, Kohnen R, Banik N, Schoen SW, Hornyak M. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol 2011; 258: 1046-1054.
27. Calne SM, Lidstone SC, Kumar A. Psychosocial issues in young-onset Parkinsons disease: current research and challenges. Parkinsonism Relat Disord 2008; 14: 143-150.
28. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci 2011; 31: 14436-14449.
29. Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in Parkinsonism. P Natl Acad Sci USA 2011; 108: 6632-6637.
30. Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. Neurology 2015; 84: 2422-2429.
31. Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinsons disease. Exp Neurol 2012; 233: 79-86.
32. Hong H, Kim BS, Im HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J 2016; 20 (Suppl. 1): S2- S7.